翰思艾泰生物医药科技（武汉）股份有限公司（翰思艾泰-B，股份代号：03378）于2026年6月4日发布公告，披露在香港联交所场内回购27,700股H股普通股，约占该公司已发行股份（不包括库藏股）总数的0.02%。每股回购价格介乎每股港币27.20元至28.00元，合计付出约76.54万港元。
经此次回购后，翰思艾泰-B已发行股本合计136,218,830股，其中135,213,130股为已发行流通股，1,005,700股为库存股份。公司已于2026年2月12日通过购回授权，可回购股份总数为13,621,883股，截至公告日公司已累计购回1,005,700股，占授权通过当日已发行股份总数的0.7383%。公告同时显示，该公司在本次回购实施后30天内不进行任何新股发行或库存股份再出售或转让，暂定至2026年7月4日。
公司确认已遵守香港联交所证券上市规则及相关法律法规的规定。公告由公司董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.